Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm

被引:5
作者
Hu, Shanshan [1 ]
Gu, Shengying [1 ]
Wang, Shuowen [1 ]
Qi, Chendong [1 ]
Shi, Chenyang [1 ]
Qian, Fengdan [1 ]
Fan, Guorong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Clin Pharm, Shanghai 200080, Peoples R China
基金
中国国家自然科学基金;
关键词
bladder cancer; machine learning; immunotherapy; prognosis; ferroptosis; FERROPTOSIS;
D O I
10.3390/genes13061073
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The important roles of machine learning and ferroptosis in bladder cancer (BCa) are still poorly understood. In this study, a comprehensive analysis of 19 ferroptosis-related genes (FRGs) was performed in 1322 patients with BCa from four independent patient cohorts and a pan-cancer cohort of 9824 patients. Twelve FRGs were selected through machine learning algorithm to construct the prognosis model. Significantly differential survival outcomes (hazard ratio (HR) = 2.09, 95% confidence interval (CI): 1.55-2.82, p < 0.0001) were observed between patients with high and low ferroptosis scores in the TCGA cohort, which was also verified in the E-MTAB-4321 cohort (HR = 4.71, 95% CI: 1.58-14.03, p < 0.0001), the GSE31684 cohort (HR = 1.76, 95% CI: 1.08-2.87, p = 0.02), and the pan-cancer cohort (HR = 1.15, 95% CI: 1.07-1.24, p < 0.0001). Tumor immunity-related pathways, including the IL-17 signaling pathway and JAK-STAT signaling pathway, were found to be associated with the ferroptosis score in BCa through a functional enrichment analysis. Further verification in the IMvigor210 cohort revealed the BCa patients with high ferroptosis scores tended to have worse survival outcome after receiving tumor immunotherapy. Significantly different ferroptosis scores could also be found between BCa patients with different reactions to treatment with immune checkpoint inhibitors.
引用
收藏
页数:11
相关论文
共 33 条
[1]   The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review [J].
Abufaraj, Mohammad ;
Dalbagni, Guido ;
Daneshmand, Siamak ;
Horenblas, Simon ;
Kamat, Ashish M. ;
Kanzaki, Ryu ;
Zlotta, Alexandre R. ;
Shariat, Shahrokh F. .
EUROPEAN UROLOGY, 2018, 73 (04) :543-557
[2]   Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion [J].
Angeli, Jose Pedro Friedmann ;
Krysko, Dmitri, V ;
Conrad, Marcus .
NATURE REVIEWS CANCER, 2019, 19 (07) :405-414
[3]   Prospects and progress of immunotherapy for bladder cancer [J].
Boegemann, Martin ;
Aydin, Ahmet Murat ;
Bagrodia, Aditya ;
Krabbe, Laura-Maria .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (11) :1417-1431
[4]   Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy [J].
Di Pilato, Mauro ;
Kim, Edward Y. ;
Cadilha, Bruno L. ;
Prussmann, Jasper N. ;
Nasrallah, Mazen N. ;
Seruggia, Davide ;
Usmani, Shariq M. ;
Misale, Sandra ;
Zappulli, Valentina ;
Carrizosa, Esteban ;
Mani, Vinidhra ;
Ligorio, Matteo ;
Warner, Ross D. ;
Medoff, Benjamin D. ;
Marangoni, Francesco ;
Villani, Alexandra-Chloe ;
Mempel, Thorsten R. .
NATURE, 2019, 570 (7759) :112-+
[5]   Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death [J].
Dixon, Scott J. ;
Lemberg, Kathryn M. ;
Lamprecht, Michael R. ;
Skouta, Rachid ;
Zaitsev, Eleina M. ;
Gleason, Caroline E. ;
Patel, Darpan N. ;
Bauer, Andras J. ;
Cantley, Alexandra M. ;
Yang, Wan Seok ;
Morrison, Barclay, III ;
Stockwell, Brent R. .
CELL, 2012, 149 (05) :1060-1072
[6]   Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type [J].
Fabre, Joseph ;
Giustiniani, Jerome ;
Garbar, Christian ;
Antonicelli, Frank ;
Merrouche, Yacine ;
Bensussan, Armand ;
Bagot, Martine ;
Al-Daccak, Reem .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (09)
[7]   Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma [J].
Hedegaard, Jakob ;
Lamy, Philippe ;
Nordentoft, Iver ;
Algaba, Ferran ;
Hoyer, Soren ;
Ulhoi, Benedicte Parm ;
Vang, Soren ;
Reinert, Thomas ;
Hermann, Gregers G. ;
Mogensen, Karin ;
Thomsen, Mathilde Borg Houlberg ;
Nielsen, Morten Muhlig ;
Marquez, Mirari ;
Segersten, Ulrika ;
Aine, Mattias ;
Hoglund, Mattias ;
Birkenkamp-Demtroder, Karin ;
Fristrup, Niels ;
Borre, Michael ;
Hartmann, Arndt ;
Stoehr, Robert ;
Wach, Sven ;
Keck, Bastian ;
Seitz, Anna Katharina ;
Nawroth, Roman ;
Maurer, Tobias ;
Tulic, Cane ;
Simic, Tatjana ;
Junker, Kerstin ;
Horstmann, Marcus ;
Harving, Niels ;
Petersen, Astrid Christine ;
Luz Calle, M. ;
Steyerberg, Ewout W. ;
Beukers, Willemien ;
van Kessel, Kim E. M. ;
Jensen, Jorgen Bjerggaard ;
Pedersen, Jakob Skou ;
Malmstrom, Per-Uno ;
Malats, Nuria ;
Real, Francisco X. ;
Zwarthoff, Ellen C. ;
Orntoft, Torben Falck ;
Dyrskjot, Lars .
CANCER CELL, 2016, 30 (01) :27-42
[8]   Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors [J].
Hwang, Inhwan ;
Park, Inkeun ;
Yoon, Shin-kyo ;
Lee, Jae Lyun .
CLINICAL GENITOURINARY CANCER, 2020, 18 (02) :E122-E133
[9]   Summaries of affymetrix GeneChip probe level data [J].
Irizarry, RA ;
Bolstad, BM ;
Collin, F ;
Cope, LM ;
Hobbs, B ;
Speed, TP .
NUCLEIC ACIDS RESEARCH, 2003, 31 (04) :e15
[10]   First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication [J].
Lemery, Steven ;
Keegan, Patricia ;
Pazdur, Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (15) :1409-1412